Phenotype/Genotype Relationship in Left Ventricular Noncompaction: Ion Channel Gene Mutations Are Associated With Preserved Left Ventricular Systolic Function and Biventricular Noncompaction: Phenotype/Genotype of Noncompaction.


Journal

Journal of cardiac failure
ISSN: 1532-8414
Titre abrégé: J Card Fail
Pays: United States
ID NLM: 9442138

Informations de publication

Date de publication:
06 2021
Historique:
received: 06 08 2020
revised: 16 01 2021
accepted: 17 01 2021
entrez: 5 6 2021
pubmed: 6 6 2021
medline: 21 10 2021
Statut: ppublish

Résumé

Few data exist concerning genotype-phenotype relationships in left ventricular noncompaction (LVNC). From a multicenter French Registry, we report the genetic and clinical spectrum of 95 patients with LVNC, and their genotype-phenotype relationship. Among the 95 LVNC, 45 had at least 1 mutation, including 14 cases of mutation in ion channel genes. In a complementary analysis including 16 additional patients with ion channel gene mutations, for a total of 30 patients with ion channel gene mutation, we found that those patients had higher median LV ejection fraction (60% vs 40%; P < .001) and more biventricular noncompaction (53.1% vs 18.5%; P < .001) than the 81 other patients with LVNC. Among them, both the 19 patients with an HCN4 mutation and the 11 patients with an RYR2 mutation presented with a higher LV ejection fraction and more frequent biventricular noncompaction than the 81 patients with LVNC but with no mutation in the ion channel gene, but only patients with HCN4 mutation presented with a lower heart rate. Ion channel gene mutations should be searched systematically in patients with LVNC associated with either bradycardia or biventricular noncompaction, particularly when LV systolic function is preserved. Identifying causative mutations is of utmost importance for genetic counselling of at-risk relatives of patients affected by LVNC.

Sections du résumé

BACKGROUND
Few data exist concerning genotype-phenotype relationships in left ventricular noncompaction (LVNC).
METHODS AND RESULTS
From a multicenter French Registry, we report the genetic and clinical spectrum of 95 patients with LVNC, and their genotype-phenotype relationship. Among the 95 LVNC, 45 had at least 1 mutation, including 14 cases of mutation in ion channel genes. In a complementary analysis including 16 additional patients with ion channel gene mutations, for a total of 30 patients with ion channel gene mutation, we found that those patients had higher median LV ejection fraction (60% vs 40%; P < .001) and more biventricular noncompaction (53.1% vs 18.5%; P < .001) than the 81 other patients with LVNC. Among them, both the 19 patients with an HCN4 mutation and the 11 patients with an RYR2 mutation presented with a higher LV ejection fraction and more frequent biventricular noncompaction than the 81 patients with LVNC but with no mutation in the ion channel gene, but only patients with HCN4 mutation presented with a lower heart rate.
CONCLUSIONS
Ion channel gene mutations should be searched systematically in patients with LVNC associated with either bradycardia or biventricular noncompaction, particularly when LV systolic function is preserved. Identifying causative mutations is of utmost importance for genetic counselling of at-risk relatives of patients affected by LVNC.

Identifiants

pubmed: 34088380
pii: S1071-9164(21)00010-5
doi: 10.1016/j.cardfail.2021.01.007
pii:
doi:

Substances chimiques

HCN4 protein, human 0
Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels 0
Ion Channels 0
Muscle Proteins 0
Potassium Channels 0
RyR2 protein, human 0
Ryanodine Receptor Calcium Release Channel 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

677-681

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Marie Cambon-Viala (M)

Cardiology Department, APHM, La Timone Hospital, Marseille, France.

Hilla Gerard (H)

Cardiology Department, APHM, La Timone Hospital, Marseille, France.

Karine Nguyen (K)

Département de génétique médicale, APHM, Hôpital d'enfants de la Timone, Marseille, France; Aix Marseille University, INSERM, Marseille Medical Genetics, Faculté de Médecine, France.

Pascale Richard (P)

APHP, Functional Unit of Cardiogénétique et Myogénétique, Service de Biochimie Métabolique, Hôpitaux Universitaires de la Pitié-Salpêtrière-Charles Foix, Paris, France; Sorbonne Universités, UPMC Univ. Paris 06, INSERM, UMR_S 1166 and ICAN Institute for Cardiometabolism and Nutrition, Paris, France.

Flavie Ader (F)

APHP, Functional Unit of Cardiogénétique et Myogénétique, Service de Biochimie Métabolique, Hôpitaux Universitaires de la Pitié-Salpêtrière-Charles Foix, Paris, France; Sorbonne Universités, UPMC Univ. Paris 06, INSERM, UMR_S 1166 and ICAN Institute for Cardiometabolism and Nutrition, Paris, France.

Jean-François Pruny (JF)

APHP, Centre de référence pour les maladies cardiaques héréditaires, Hôpital Pitié-Salpêtrière, Paris, France.

Erwan Donal (E)

Service de Cardiologie, Centre Hospitalier Régional Universitaire Pontchaillou, Rennes, France.

Jean-Christophe Eicher (JC)

Service de Cardiologie, CHU Dijon Bourgogne - Hôpital François Mitterrand, 2 bd Maréchal de Lattre de Tassigny, Dijon, France.

Olivier Huttin (O)

Service de Cardiologie, CHU de Nancy, Hôpitaux de Brabois, rue du Morvan, Vandoeuvre-lès-Nancy, France.

Christine Selton-Suty (C)

Service de Cardiologie, CHU de Nancy, Hôpitaux de Brabois, rue du Morvan, Vandoeuvre-lès-Nancy, France.

Pascale Raud-Raynier (P)

Service de Cardiologie, CHU de Poitiers, Poitiers, France.

Guillaume Jondeau (G)

APHP, Service Cardiologie, CHU Paris Nord- Val de Seine - Hôpital Xavier Bichat-Claude Bernard, Paris, France.

Nicolas Mansencal (N)

APHP, Service de Cardiologie, CHU Ambroise Paré, Boulogne Billancourt, France.

Caroline Sawka (C)

Centre de génétique et FHU TRANSLAD, Hôpital d'Enfants et Université de Bourgogne, Dijon, France.

Anne-Claire Casalta (AC)

Cardiology Department, APHM, La Timone Hospital, Marseille, France.

Nicolas Michel (N)

Cardiology Department, APHM, La Timone Hospital, Marseille, France.

Valeria Donghi (V)

Cardiology Department, APHM, La Timone Hospital, Marseille, France.

Hélène Martel (H)

Cardiology Department, APHM, La Timone Hospital, Marseille, France.

Laurence Faivre (L)

Centre de génétique et FHU TRANSLAD, Hôpital d'Enfants et Université de Bourgogne, Dijon, France.

Philippe Charron (P)

Sorbonne Universités, UPMC Univ. Paris 06, INSERM, UMR_S 1166 and ICAN Institute for Cardiometabolism and Nutrition, Paris, France; APHP, Centre de référence pour les maladies cardiaques héréditaires, Hôpital Pitié-Salpêtrière, Paris, France.

Gilbert Habib (G)

Cardiology Department, APHM, La Timone Hospital, Marseille, France; Aix Marseille Univ, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France. Electronic address: gilbert.habib3@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH